164579-32-2
164579-32-2 結構式
基本信息
泮托拉唑鈉水合物
泮托拉唑鈉水合物1
潘托拉唑鈉1.5水
泮托拉唑鈉1.5水
泮托拉唑鈉倍半水合物
泮托拉唑鈉1.5水合物
泮托拉唑鈉倍半結晶水合物
泮托拉唑鈉水合物 EP標準品
泮托拉唑鈉系統(tǒng)適應 EP標準品
BY1023 (sodium hydrate)
SKF-96022 SODIUM HYDRATE
Pantoprazole sodium hydrate
Pantoprazole sodium sesquihydrate CRS
Pantoprazole for system suitability CRS
Pantoprazole Sodium sesqui hydrate- IP/BP/USP
6-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt hydrate (2:2:3)
1H-Benzimidazole, 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-, sodium salt, hydrate (2:3)
Pantoprazole Sodium SesquihydrateQ: What is Pantoprazole Sodium Sesquihydrate Q: What is the CAS Number of Pantoprazole Sodium Sesquihydrate Q: What is the storage condition of Pantoprazole Sodium Sesquihydrate
常見問題列表
Pantoprazole sodium hydrate (BY1023 sodium hydrate; 1-10000 μM) leads to concentration-dependent increases in endosomal pH in EMT-6 and MCF7 cells.
Pantoprazole sodium hydrate can block exosome release. Pantoprazole sodium hydrate inhibits the activity of V-H
+
-ATPase and impaires the ability of tumour cells (melanomas, adenocarcinomas, and lymphoma cell lines) to acidify the extracellular medium
Pantoprazole sodium hydrate (BY1023 sodium hydrate; 200 mg/kg; IP; once a week for 3 weeks) significantly increases tumor growth delay of MCF-7 xenografts combined with Doxorubicin.
Pantoprazole sodium hydrate (0.3-3 mg/kg, p.o.) dose-dependently decreases both basal acid secretion in pylorus-ligated rats and the stimulated acid secretion induced by mepirizole in acute fistula rats.
| Animal Model: | Mice bearing MCF-7 or A431 xenografts |
| Dosage: | 200 mg/kg |
| Administration: | IP; once a week for 3 weeks; alone or 2 hours before Doxorubicin (6 mg/kg i.v.) |
| Result: |
Showed even greater growth delay of MCF-7 xenografts with Doxorubicin compared with the single-dose combination.
Significantly increased tumor growth delay with a single dose with Doxorubicin. There is no effect on growth delay alone. |